BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32974956)

  • 1. Case of pemphigoid with immunoglobulin G antibodies to BP180 C-terminal domain and laminin-γ1 (p200) developed after pneumococcal vaccination.
    Maki N; Hashimoto T; Yamada T; Ishii N; Tsuruta D; Demitsu T
    J Dermatol; 2021 Jan; 48(1):101-105. PubMed ID: 32974956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case of subepidermal autoimmune bullous disease with psoriasis vulgaris reacting to both BP180 C-terminal domain and laminin gamma-1.
    Ishida S; Takahashi K; Kanaoka M; Okawa T; Tateishi C; Yasukochi A; Ishii N; Li X; Hashimoto T; Aihara M
    J Dermatol; 2015 Apr; 42(4):391-3. PubMed ID: 25683229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin.
    Imanishi A; Tateishi C; Imanishi H; Sowa-Osako J; Koga H; Tsuruta D; Hashimoto T
    J Dermatol; 2015 Apr; 42(4):394-7. PubMed ID: 25708520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of anti-laminin γ1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration.
    Nakatani K; Noborio R; Nomura Y; Ueki Y; Kiyohara T; Hashimoto T
    J Dermatol; 2024 Jun; 51(6):869-872. PubMed ID: 38214494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.
    Meijer JM; Diercks GF; Schmidt E; Pas HH; Jonkman MF
    JAMA Dermatol; 2016 Aug; 152(8):897-904. PubMed ID: 27167149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of pemphigus herpetiformis with IgG antibodies to desmocollin 1 and pemphigoid with IgG antibodies to BP180 C-terminal domain and laminin γ2.
    Ohata C; Higashi Y; Yamagami J; Koga H; Ishii N; Kanekura T; Furumura M; Hashimoto T
    JAMA Dermatol; 2013 Apr; 149(4):502-4. PubMed ID: 23715433
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-p200 pemphigoid.
    Goletz S; Hashimoto T; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2014 Jul; 71(1):185-91. PubMed ID: 24767733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia.
    Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T
    J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of pemphigoid with antibodies to BP180 C-terminal domain and α3 subunit of laminin-332 associated with chronic graft-versus-host disease.
    Kawashima H; Kageji R; Hida Y; Goto T; Ishii N; Hashimoto T
    J Dermatol; 2021 Sep; 48(9):e447-e448. PubMed ID: 34114672
    [No Abstract]   [Full Text] [Related]  

  • 11. Usefulness of immunofluorescence overlay antigen mapping in the identification of autoantigen in anti-p200 pemphigoid.
    Kitayama S; Makino T; Hayashi M; Mizawa M; Ishii N; Hashimoto T; Shimizu T
    J Dermatol; 2023 Sep; 50(9):1194-1198. PubMed ID: 37082790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-p200 pemphigoid: a spectacular response to dapsone].
    Munsch C; Prey S; Joly P; Meyer N; Lamant L; Livideanu C; Viraben R; Paul C
    Ann Dermatol Venereol; 2011 Nov; 138(11):739-42. PubMed ID: 22078034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
    Raffin D; Delaplace M; Roussel A; Estève E
    Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucous membrane pemphigoid with immunoglobulin G autoantibodies against full-length and 120-kDa ectodomain of BP180.
    Choi Y; Lee SE; Fukuda S; Hashimoto T; Kim SC
    J Dermatol; 2011 Feb; 38(2):169-72. PubMed ID: 21269314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.
    Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.
    Dainichi T; Koga H; Tsuji T; Ishii N; Ohyama B; Ueda A; Natsuaki Y; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
    J Dermatol; 2010 Mar; 37(3):231-8. PubMed ID: 20507386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1 in nivolumab-associated bullous pemphigoid.
    Matsui Y; Makino T; Ishii N; Hashimoto T; Shimizu T
    Eur J Dermatol; 2019 Oct; 29(5):554-555. PubMed ID: 31570332
    [No Abstract]   [Full Text] [Related]  

  • 18. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.
    Hofmann S; Thoma-Uszynski S; Hunziker T; Bernard P; Koebnick C; Stauber A; Schuler G; Borradori L; Hertl M
    J Invest Dermatol; 2002 Nov; 119(5):1065-73. PubMed ID: 12445194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab.
    Sarrazin M; Jouen F; Duvert-Lehembre S
    Ann Dermatol Venereol; 2021 Mar; 148(1):60-62. PubMed ID: 33478824
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-laminin γ1 pemphigoid associated with ulcerative colitis and psoriasis vulgaris showing autoantibodies to laminin γ1, type XVII collagen and laminin-332.
    Akasaka E; Nakano H; Korekawa A; Fukui T; Kaneko T; Koga H; Hashimoto T; Sawamura D
    Eur J Dermatol; 2015 Apr; 25(2):198-9. PubMed ID: 25787875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.